Pharmaceutical Executive
Ilogistica has built a brand new warehouse facility with the latest technology to keep up with outsourcing demands
With the reform of CENABAST requiring the outsourcing of all its distribution activities, logistics providers are stepping up to meet the demand of pharmaceutical laboratories. Just outside of Santiago, iLogistica has built a brand new 8,000m2 storage warehouse with the latest technology for the most efficient distribution of pharmaceutical products. Having reconstructed almost from scratch after the earthquake in February of 2010, the company has refurbished itself to become the strategic partner for the industry. General manager, Raul Zamorano, explains his company's comparative advantage to serve the pharmaceutical industry: "being an entirely independent company that is not linked to any pharmaceutical laboratory, we can ensure the utmost confidentiality of our clients' data and product information. We also have no alliance with any of the players in the industry and this allows us to act freely always looking to serve our clients in the most efficient and effective way possible. In this sense we are positioned to become a trustworthy partner for any international company that wishes to distribute their products in Chile and who might have reservations about the safety of their company's data." The company has gone as far as developing a custom-made software platform that allows the greatest adaptability to the demands of its customers. "In order to provide the best traceability for our clients we have developed our own software platform that allows full customization to each one of our clients' needs," explains Zamorano.
Raul Zamorano, General Manager, iLogistica
iLogistica Santiago warehouse
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.